Kenilworth, N.J.-based Merck will pay Orion $290 million in a global development and commercialization agreement for the Finland-based pharmaceutical company’s oral inhibitor that aims to treat advanced prostate cancer.
Read the full post on Becker's Hospital Review - Healthcare News
